Metastatic
ovarian cancer is the leading cause of death among women with gynecologic
malignancies in the United States. The lack of effective treatment for patients with advanced
ovarian cancer warrants development of
innovative therapies.
Cancer therapy using oncolytic viruses represents a promising new approach for controlling
tumors. Vaccinia virus has been shown to preferentially infect
tumor cells but not normal tissue. However, oncolytic
therapy using recombinant viruses faces the limitation of viral clearance due to generation of
neutralizing antibodies. In the current study, we found that
cyclooxygenase-2 (Cox-2) inhibitors circumvented this limitation, enabling repeated administration of vaccinia virus without losing infectivity. We quantified the antivaccinia antibody response using
enzyme-linked
immunosorbent assay (ELISA) and neutralization assays to show that treatment of
Cox-2 inhibitors inhibited the generation of
neutralizing antibodies. Furthermore, we showed that combination treatment of
Cox-2 inhibitors with vaccinia virus was more effective that either treatment alone in treating MOSEC/luc
tumor-bearing mice. Thus, the combination of
Cox-2 inhibitors and vaccinia virus represents a potential innovative approach to controlling ovarian
tumors.